Immunosuppressant Timing Before Elective Shoulder Replacement in Rheumatology Patients
Compares stopping immunosuppressant drugs for longer versus shorter periods before shoulder replacement in rheumatic disease.
Key facts
- Who runs it
- NYU Langone Health
- Where
- New York, United StatesSee the site
- Trial code
- Registry title
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 80 people, planned
- Started
- 12 Dec 2025
- Expected to end
- Jan 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Methotrexate
- Sulfasalazine
- Hydroxychloroquine
- Leflunomide
- Azathioprine
- Mycophenolate
- Cyclosporine
- Tacrolimus
- Etanercept
- Adalimumab
- Golimumab
- Certolizumab
- Infliximab
- Rituximab
- Belimumab
- Tocilizumab
- Anakinra
- Canakinumab
- Abatacept
- Secukinumab
- Ixekizumab
- Bimekizumab
- Ustekinumab
- Guselkumab
- Risankizumab
- Tofacitinib
- Upadacitinib
- Record updated
- 9 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a rheumatic disease who take immunosuppressant medicine and are scheduled for an elective total shoulder replacement.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- A rheumatic disease such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, lupus, juvenile idiopathic arthritis, polymyalgia rheumatica, giant cell arteritis or vasculitis.
- Earlier treatment
- Must have been on active immunosuppression for at least 3 months before the planned surgery.
Main reasons for not taking part
- Active infection or cancer
- Shoulder replacement because of a fracture or tumor
- Pregnancy or breastfeeding
- Severe lupus with marked disease activity
- Cannot give written informed consent
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adults aged 18 years and older at the time of informed consent
- Diagnosis of rheumatic disease: rheumatoid arthritis (RA), psoriatic arthritis (PA) , ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA), spondyloarthritis, polymyalgia rheumatica, giant cell arteritis, vasculitis, granulomatosis with polyangiitis, dermatomyositis, polymyositis, and inflammatory bowel disease-associated arthritis
- On active immunosuppression for at least 3 months prior to scheduled surgery
- Scheduled for elective total shoulder arthroplasty
- Able and willing to provide written informed consent prior to any study specific procedures
Who cannot take part
- Unable or without capacity to provide written informed consent prior to any study specific procedures
- Patients with active infections or malignancies
- Patients with severe SLE with marked activity - as they should be offered enrollment in the observational arm. All such patients should remain on treatment to avoid worsening of disease activity
- Patients undergoing shoulder arthroplasty for fracture or tumor
- Pregnancy or breastfeeding
- Unable to provide informed consent
Where in United States
- NYU Langone HealthNew York, United StatesContact: Thomas ChalothronTaking people
About the trial
What the trial wants to find out
The purpose of this study is to assess the incidence of rheumatologic flares, changes in pain scores (VAS), changes in functional outcomes (PROMIS), wound complications, surgical site infections, and return trips to the operating room for rheumatology patients following shoulder replacements, comparing those who stop their immunosuppressants preoperatively for the same amount of time as suggested in the literature for hip and knee arthroplasty versus those who hold the medications for a shorter period of time preoperatively.
The 2 groups in the trial
- Standard holdExisting treatment, for comparison
Patients will follow the standard perioperative immunosuppressant hold protocol based on guidelines from hip and knee arthroplasty literature. The duration of the hold is determined by medication half-life and infection risk considerations. Postoperatively, medications will be restarted approximately 2 weeks after surgery (+/- 2 days), contingent on wound healing and infection status.
Treatment: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, and Secukinumab
- Shorter holdTreatment being tested
Patients will follow an abbreviated immunosuppressant hold protocol, withhold durations modified based on drug pharmacokinetics to allow a shorter preoperative discontinuation period. Medications will be prescribed as usual by the patient's rheumatologist, only adjusting the interval between last preoperative dose and surgery. The rheumatologist will relay the number of weeks/days between the last dose and surgery date. Postoperatively, medications will be restarted approximately 1 week after surgery (+/- 2 days), provided there are no signs of infection or wound healing complications. Route of Administration
Treatment: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, and Secukinumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
- Plain-language title
- Immunosuppressant Timing Before Elective Shoulder Replacement in Rheumatology PatientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 July 2026